Because clinical conditions associated with hepatic steatosis are producing substantial health care costs, it is reasonable to assume that genetic variants in the PNPLA3 and TM6SF2 genes, as promoters of liver fat, might be associated with health care utilization. The gene discussed is PNPLA3; the disease is fatty liver disease.